
The cannabis and hemp industries continue their rapid growth, but access to reliable financial services remains one of the thorniest compliance and operational challenges. In July 2025, a coalition of 32 bipartisan state Attorneys General renewed calls on Congress to pass the SAFER Banking Act, underscoring how cash-heavy operations in state-regulated markets pose lingering risks for public safety and business transparency. Read the AGs' letter (PDF)
While the SAFER Banking Act (an updated version of the SAFE Banking Act) would not federally legalize cannabis, it is intended to shield financial institutions from liability for serving state-legal cannabis and (by extension) hemp businesses. This could unlock new payment, lending, and investment channels. But as of September 2025, SAFE(R) remains stalled, leaving businesses dependent on a slim field of willing banks and credit unions, and placing robust compliance at the center of any successful account onboarding.
Despite extensive state legalization, most major banks steer clear of cannabis due to federal prohibitions and anti-money-laundering (AML) risks. This has resulted in:
A passage of SAFER would dramatically expand the pool of financial partners—but won’t eliminate foundational compliance obligations rooted in federal law. Operators must keep pace with FinCEN (Financial Crimes Enforcement Network) expectations and prepare now for higher scrutiny to accelerate onboarding when more banks finally open their doors.
FinCEN guidance—originally issued in 2014 for marijuana-related businesses (MRBs) and updated for hemp in 2019 and 2020—establishes that banks may serve state-legal cannabis/hemp businesses if they implement rigorous compliance programs. Key points:
See FinCEN’s formal marijuana guidance: FIN-2014-G001 and hemp guidance (PDF)
A crucial point that compliance teams must grasp is how banks differentiate non-intoxicating hemp CBD products (legal under the 2018 Farm Bill) from intoxicating hemp derivatives (such as Delta-8 THC or Delta-10 THC products).
If you sell, distribute, or process intoxicating hemp compounds, expect underwriting requirements at least as strict as those for state-legal cannabis—often with more frequent reviews or additional SAR triggers.
Banks typically require valid state and local licenses for all activities—cultivation, processing, manufacturing, and sales/dispensary operations. Licenses must be renewed and in good standing.
COAs must come from accredited third-party labs, proving that products meet the legal THC threshold and are free from contaminants.
Cannabis businesses are often asked for access to their track-and-trace system (e.g., Metrc, BioTrack) to verify product inventories, sales, and regulatory compliance.
Expect to submit:
Some banks will conduct a mini audit of your compliance program: anti-money laundering policies, employee training, recordkeeping, and evidence of internal controls.
Historical sales data, bank statements, and reasonable forward-looking projections are often requested to help the financial institution model expected risk and cash flow patterns.
Per FinCEN guidance, banks must file:
Hemp clients may still be flagged for SARs if a bank believes they are misrepresenting product type, using proceeds for illegal marijuana activity, or failing to meet recordkeeping standards.
To maximize your chances of onboarding with a willing bank or credit union now—and to be prepared to move quickly if SAFER passes—cannabis and hemp businesses should:
The immediate effect of SAFER would be a wider pool of banks and credit unions willing to take on state-legal cannabis and hemp clients. However, robust compliance processes won’t disappear:
2025’s banking landscape is in transition—but not yet solved. No matter what happens in Congress, being proactive about compliance is the best investment for cannabis and hemp businesses.
Are you ready for the next phase of cannabis banking? Bookmark CannabisRegulations.ai and leverage the latest tools and updates to stay ahead on licensing, compliance, and regulatory changes that impact your financial options.

The cannabis and hemp industries continue their rapid growth, but access to reliable financial services remains one of the thorniest compliance and operational challenges. In July 2025, a coalition of 32 bipartisan state Attorneys General renewed calls on Congress to pass the SAFER Banking Act, underscoring how cash-heavy operations in state-regulated markets pose lingering risks for public safety and business transparency. Read the AGs' letter (PDF)
While the SAFER Banking Act (an updated version of the SAFE Banking Act) would not federally legalize cannabis, it is intended to shield financial institutions from liability for serving state-legal cannabis and (by extension) hemp businesses. This could unlock new payment, lending, and investment channels. But as of September 2025, SAFE(R) remains stalled, leaving businesses dependent on a slim field of willing banks and credit unions, and placing robust compliance at the center of any successful account onboarding.
Despite extensive state legalization, most major banks steer clear of cannabis due to federal prohibitions and anti-money-laundering (AML) risks. This has resulted in:
A passage of SAFER would dramatically expand the pool of financial partners—but won’t eliminate foundational compliance obligations rooted in federal law. Operators must keep pace with FinCEN (Financial Crimes Enforcement Network) expectations and prepare now for higher scrutiny to accelerate onboarding when more banks finally open their doors.
FinCEN guidance—originally issued in 2014 for marijuana-related businesses (MRBs) and updated for hemp in 2019 and 2020—establishes that banks may serve state-legal cannabis/hemp businesses if they implement rigorous compliance programs. Key points:
See FinCEN’s formal marijuana guidance: FIN-2014-G001 and hemp guidance (PDF)
A crucial point that compliance teams must grasp is how banks differentiate non-intoxicating hemp CBD products (legal under the 2018 Farm Bill) from intoxicating hemp derivatives (such as Delta-8 THC or Delta-10 THC products).
If you sell, distribute, or process intoxicating hemp compounds, expect underwriting requirements at least as strict as those for state-legal cannabis—often with more frequent reviews or additional SAR triggers.
Banks typically require valid state and local licenses for all activities—cultivation, processing, manufacturing, and sales/dispensary operations. Licenses must be renewed and in good standing.
COAs must come from accredited third-party labs, proving that products meet the legal THC threshold and are free from contaminants.
Cannabis businesses are often asked for access to their track-and-trace system (e.g., Metrc, BioTrack) to verify product inventories, sales, and regulatory compliance.
Expect to submit:
Some banks will conduct a mini audit of your compliance program: anti-money laundering policies, employee training, recordkeeping, and evidence of internal controls.
Historical sales data, bank statements, and reasonable forward-looking projections are often requested to help the financial institution model expected risk and cash flow patterns.
Per FinCEN guidance, banks must file:
Hemp clients may still be flagged for SARs if a bank believes they are misrepresenting product type, using proceeds for illegal marijuana activity, or failing to meet recordkeeping standards.
To maximize your chances of onboarding with a willing bank or credit union now—and to be prepared to move quickly if SAFER passes—cannabis and hemp businesses should:
The immediate effect of SAFER would be a wider pool of banks and credit unions willing to take on state-legal cannabis and hemp clients. However, robust compliance processes won’t disappear:
2025’s banking landscape is in transition—but not yet solved. No matter what happens in Congress, being proactive about compliance is the best investment for cannabis and hemp businesses.
Are you ready for the next phase of cannabis banking? Bookmark CannabisRegulations.ai and leverage the latest tools and updates to stay ahead on licensing, compliance, and regulatory changes that impact your financial options.